BIOGEN INC. Return Tang Equity
Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
- BIOGEN INC. return tang equity for the quarter ending 2026-03-31 was 27.95%, a 48.54% decline year-over-year.
- BIOGEN INC. return tang equity for the quarter ending 2025-12-31 was 29.48%, a 57.51% decline year-over-year.
- BIOGEN INC. return tang equity for the quarter ending 2025-09-30 was 38.40%, a 54.48% decline year-over-year.
- BIOGEN INC. return tang equity for the quarter ending 2025-06-30 was 44.02%, a 37.96% decline year-over-year.
- BIOGEN INC. return tang equity for fiscal 2025 was 29.48%, a 57.51% decline from fiscal 2024.
- BIOGEN INC. return tang equity for fiscal 2024 was 69.37%, a 62.58% increase from fiscal 2023.
- BIOGEN INC. return tang equity for fiscal 2023 was 42.67%, a 18.03% decline from fiscal 2022.
- BIOGEN INC. return tang equity for fiscal 2022 was 52.05%, a 6.18% increase from fiscal 2021.
- Available history
- 2007-12-31 to 2026-03-31
- Data captured
Historical Return Tang Equity
Annual Return Tang Equity
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |